OSR Holdings, Inc. (NASDAQ:OSRH) Short Interest Up 42.8% in March

Posted by Doug Wharley on Mar 28th, 2026

OSR Holdings, Inc. (NASDAQ:OSRH – Get Free Report) saw a large increase in short interest in March. As of March 13th, there was short interest totaling 376,966 shares, an increase of 42.8% from the February 26th total of 264,011 shares. Based on an average daily volume of 523,223 shares, the short-interest ratio is presently 0.7 days. Currently, 3.7% of the company’s stock are short sold.

OSR Stock Performance

NASDAQ:OSRH traded up $0.02 during mid-day trading on Friday, hitting $0.46. The stock had a trading volume of 3,114,662 shares, compared to its average volume of 891,391. OSR has a twelve month low of $0.38 and a twelve month high of $3.30. The stock has a market cap of $11.93 million, a price-to-earnings ratio of -0.41 and a beta of 1.54. The company’s 50 day simple moving average is $0.51 and its 200 day simple moving average is $0.59.

Institutional Trading of OSR

An institutional investor recently bought a new position in OSR stock. Susquehanna International Group LLP bought a new position in shares of OSR Holdings, Inc. (NASDAQ:OSRH – Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned about 0.37% of OSR at the end of the most recent quarter. 55.30% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of OSR in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

View Our Latest Stock Analysis on OSR

OSR Company Profile

(Get Free Report)

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.